

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

U.S.PATENTS						<input type="button" value="Remove"/>
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6653301	B2	2003-11-25	Vertex Pharmaceuticals Incorporated	
	2	6989385	B2	2006-01-24	Vertex Pharmaceuticals Incorporated	
	3	6664247	B2	2003-12-16	Bebbington et al.	
	4	6653300	B2	2003-11-25	Bebbington et al.	
	5	7087603	B2	2006-08-08	Bebbington et al.	
	6	6656939	B2	2003-12-02	Bebbington et al.	
	7	3755322		1973-08-28	Ciba-Geigy Corporation	
	8	6841579	B1	2005-01-11	Sugen, Inc.	

/Tamthom Truong/

02/08/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

9	3133081		1964-05-12	Smith Line & French Laboratories	
10	3935183		1976-01-27	Imperial Chemical Industries Limited	
11	3998951		1976-12-21	FMC Corporation	
12	4051252		1977-09-27	Bayer Aktiengesellschaft	
13	4493726		1985-01-15	Ciba Geigy Corporation	
14	5972946		1999-10-26	Dainippon Pharmaceutical Co., Ltd.	
15	6093716		2000-07-25	Celltech Therapeutics, Limited	
16	6277989	B1	2001-08-21	Scios, Inc.	
17	6579983	B1	2003-06-17	Celltech R&D Limited	
18	6660731	B2	2003-12-09	Vertex Pharmaceuticals Incorporated	
19	6184226	B1	2001-02-06	Scios Inc.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

20	6589958	B1	2003-07-08	Bristol-Myers Squibb Pharma Company	
21	7008948	B2	2006-03-07	Vertex Pharmaceuticals, Incorporated	
22	6696452	B2	2004-02-24	Vertex Pharmaceuticals Incorporated	
23	7098330	B2	2006-08-29	Vertex Pharmaceuticals Incorporated	
24	6660731	B2	2003-12-09	Vertex Pharmaceuticals Incorporated	
25	6613776	B2	2003-09-02	Vertex Pharmaceuticals Incorporated	
26	6638926	B2	2003-10-28	Vertex Pharmaceuticals Incorporated	
27	6610677	B2	2003-08-26	Vertex Pharmaceuticals Incorporated	
28	7115739	B2	2006-10-03	Vertex Pharmaceuticals Incorporated	
29	7179826	B2	2007-02-20	Vertex Pharmaceuticals Incorporated	
30	6846928	B2	2005-01-25	Vertex Pharmaceuticals Incorporated	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPW00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

31	7091343	B2	2006-08-15	Vertex Pharmaceuticals Incorporated	
32	4540698		1985-09-10	Mitsui Toatsu Chemicals Incorporated	
33	4711951		1987-12-08	Pharmacia Aktiebolag	
34	5124441		1992-06-23	Pharmacia Aktiebolag	
35	6562971	B2	2003-05-13	BASF Aktiengesellschaft	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code†	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020065270	A1	2002-05-30	Bristol-Myers Squibb Company	
	2	20010018436	A1	2001-08-30	Tularik Inc.	
	3	20020052386	A1	2002-05-02	Armistead et al.	
	4	20030004164	A1	2003-01-02	Bebbington et al.	

/Tamthom Truong/

02/08/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

5	20050038023	A1	2005-02-17	Bebbington et al.	
6	20040214814	A1	2004-10-28	Bebbington et al.	
7	20030105090	A1	2003-06-05	Bebbington et al.	
8	20040157893	A1	2004-08-12	Bebbington et al.	
9	20030069239	A1	2003-04-10	Cytovia, Inc.	
10	20030069248	A1	2003-04-10	Chakravarty et al.	
11	20030087922	A1	2003-05-08	Bethiel et al.	
12	20030187002	A1	2003-10-02	Mortlock et al.	
13	20060270660	A1	2006-11-30	Charier et al.	
14	20030064982	A1	2003-04-03	Davies et al.	
15	20040009981	A1	2004-01-15	Bebbington et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10775699
Filing Date		2004-02-10
First Named Inventor	David Bebbington	
Art Unit		1624
Examiner Name	Tamthom Ngo Truong	
Attorney Docket Number	VPI/00-130-07 DIV US	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

If you wish to add additional U.S. Published Application citation information please click the Add button								
FOREIGN PATENT DOCUMENTS								
						<input type="button" value="Add"/>		
						<input type="button" value="Remove"/>		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0136976	EP	A2	1985-04-10	Ciba-Geigy AG		<input type="checkbox"/>
	2	0012497	WO	A2	2000-03-09	Scios Inc.		<input type="checkbox"/>
	3	0144242	WO	A1	2001-06-21	Bristol-Myers Squibb Co.		<input type="checkbox"/>
	4	0247690	WO	A1	2002-06-20	Cytovia, Inc.		<input checked="" type="checkbox"/>
	5	0224667	WO	A1	2002-03-28	Merck Patent GMBH		<input type="checkbox"/>
	6	9614843	WO	A2	1996-05-23	Cor Therapeutics, Inc.		<input type="checkbox"/>
	7	9509851	WO	A1	1995-04-13	Ciba-Geigy AG		<input type="checkbox"/>
	8	9709325	WO	A1	1997-03-13	Signal Pharmaceuticals, Inc.		<input type="checkbox"/>
	9	9719065	WO	A1	1997-05-29	Celltech Therapeutics Limited		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

10	9811095	WO	A1	1998-03-19	Celltech Therapeutics Limited	<input type="checkbox"/>
11	9941253	WO	A1	1999-08-19	Tularik Inc.	<input type="checkbox"/>
12	0140215	WO	A1	2001-06-07	Pfizer Products Inc.	<input type="checkbox"/>
13	0147879	WO	A1	2001-07-05	Icos Corporation	<input type="checkbox"/>
14	0179198	WO	A1	2001-10-25	Agouron Pharmaceuticals, Inc.	<input type="checkbox"/>
15	0160816	WO	A1	2001-08-23	Amgen Inc.	<input type="checkbox"/>
16	0039101	WO	A1	2000-07-06	AstraZeneca UK Limited	<input type="checkbox"/>
17	0164655	WO	A1	2001-09-07	AstraZeneca AB	<input type="checkbox"/>
18	0413140	WO	A1	2004-02-12	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>
19	0250065	WO	A2	2002-06-27	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>
20	0250066	WO	A2	2002-06-27	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

21	0222601	WO	A1	2002-03-21	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>
22	0279197	WO	A1	2002-10-10	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>
23	0400833	WO	A1	2003-12-31	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>
24	9208715	WO	A1	1992-05-29	Nissan Chemical Industries, Ltd.	<input type="checkbox"/>
25	9322681	WO	A1	1993-11-11	Neurogen Corporation	<input type="checkbox"/>
26	9515758	WO	A1	1995-06-15	Rhonepoulenc Rorer Pharmaceuticals Inc.	<input type="checkbox"/>
27	9802434	WO	A1	1998-01-22	Glaxo Group Limited	<input type="checkbox"/>
28	9814450	WO	A1	1998-04-09	Novartis AG	<input type="checkbox"/>
29	9816502	WO	A1	1998-04-23	Warner-Lambert Company	<input type="checkbox"/>
30	9947154	WO	A1	1999-09-23	Cytovia, Inc.	<input type="checkbox"/>
31	9962518	WO	A1	1999-12-09	Cadus Pharmaceutical Corporation	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

	32	0042029	WO	A1	2000-07-20	Warner-Lambert Company	<input type="checkbox"/>
	33	0059509	WO	A1	2000-10-12	Novartis AG	<input type="checkbox"/>
	34	0078757	WO	A1	2000-12-28	Shionogi Bioresearch Corp.	<input type="checkbox"/>
	35	0112621	WO	A1	2001-02-22	Vertex Pharmaceuticals Incorporated	<input type="checkbox"/>
	36	0139777	WO	A1	2001-06-07	OSI Pharmaceuticals, Inc.	<input type="checkbox"/>
	37	0302312	EP	A2	1989-02-08	Bayer AG	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Wiener, J.R. et al., "Decreased Src Tyrosine Kinase Activity Inhibits Malignant Human Ovarian Cancer Tumor Growth in a Nude Mouse Model," Clinical Cancer Research, 5, 2164-2170 (1999).	<input type="checkbox"/>
	2	Warner, S.L. et al, "Targeting Aurora-2 Kinase in Cancer," Mol. Cancer Ther., 2, 589-585, 2003.	<input type="checkbox"/>
	3	Wagman, A.S. et all, "Discovery and Development of GSK3 Inhibitors for the Treatment of Type 2 Diabetes," Current Pharmaceutical Design, 10, 1105-1137 (2004).	<input type="checkbox"/>

/Tamthom Truong/

02/08/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

4	Nezu, Y. et al., "Dimethoxypyrimidines as Novel Herbicides. Part 2. Synthesis and Herbicidal Activity of Dimethoxyphenoxyphenoxypyrimidines and Analogues," <i>Pestic. Sci.</i> , 47: 115-124 (1996). <input type="checkbox"/>
5	Tanaka, T.U. et al., "Evidence that the Ipl1-Sli15 (Aurora Kinase-INCENP) Complex Promotes Chromosome Bi-orientation by Altering Kinetochore-Spindle Pole Connections," <i>Cell</i> , 108, 317-329 (2002). <input type="checkbox"/>
6	Staley, C.A. et al., "Decreased Tumorigenicity of a Human Colon Adenocarcinoma Cell Line by an Antisense Expression Vector Specific for c-Src," <i>Cell Growth & Differentiation</i> , 8: 269-274 (1997). <input type="checkbox"/>
7	Soriano, P. et al., "Targeted Disruption of the C-SIC Pmto-Oncogene Leads to Osteopetrosis in Mice," <i>Cell</i> , 64: 693-702, (1991). <input type="checkbox"/>
8	Campbell, S.F. et al., "2,4-Diamino-6,7-dimethoxyquinazolines. 3.2-(4-Heterocyly)piperazin-1-yl) Derivatives as α1-Adrenoceptor Antagonists and Antihypertensive Agents," <i>J. Med. Chem.</i> , 30, 1794-1798 (1987). <input type="checkbox"/>
9	Casanova, B. et al., "Revisión critica de la patogenia actual de la esclerosis múltiple y futuras direcciones posibles," <i>Rev. Neurol.</i> , 28 (9): 909-915 (1999). <input checked="" type="checkbox"/>
10	Cline, G.W. et al., "Effects of a Novel Glycogen Synthase Kinase-3 Inhibitor on Insulin-Stimulated Glucose Metabolism in Zucker Diabetic Fatty (fa/fa) Rats," <i>Diabetes</i> , 51, 2903-2910 (2002). <input type="checkbox"/>
11	Simone, J.V., "Oncology: Introduction" in <i>Cecil Textbook in Medicine</i> , 20th ed., Vol. 1, 1004-1010 (1996). <input type="checkbox"/>
12	Coleman, R.A., "The Biological Evaluation of New Compounds" in <i>Medicinal Chemistry: Principles and Practice</i> , King, Frank D. ed, Royal Society of Chemistry, 53-66 (1994). <input type="checkbox"/>
13	The CONDENSED CHEMICAL DICTIONARY, Sixth Edition by Arthur and Elizabeth Rose, 38 (1961). <input type="checkbox"/>
14	Damasio, A.R., "Alzheimer's Disease and Related Dementia," in <i>Cecil Textbook of Medicine</i> , 20th ed., 2: 1992-1996 (1996). <input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VPI/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

15	Rogers, E. et al., "The aurora kinase AIR-2 functions in the release of chromosome cohesion in <i>Caenorhabditis elegans</i> meiosis," <i>J. Cell Biol.</i> , 157(2): 219-229 (2002).	<input type="checkbox"/>
16	Fisher A., "Therapeutic Strategies in Alzheimer's Disease: M1 Muscarinic Agonists," <i>Jpn. J. Pharmacol.</i> , 84(2):101-12 (2000).	<input type="checkbox"/>
17	Frame, M.C., "Src in cancer: deregulation and consequences for cell behaviour," <i>Biochimica et Biophysica Acta</i> 1602, 114- 130 (2002).	<input type="checkbox"/>
18	Frampton, J.E. et al., "Pentoxifylline (Oxpentifylline) - A Review of its Therapeutic Efficacy in the Management of Peripheral Vascular and Cerebrovascular Disorder," <i>Drugs & Aging</i> , 7(6): 480-503 (1995).	<input type="checkbox"/>
19	Ganellin, C.R., "Past Approaches to Discovering New Drugs as Medicines" in <i>Medicinal Chemistry, Principles and Practices</i> . King, Frank D. ed, Royal Society of Chemistry, 189-205 (1994).	<input type="checkbox"/>
20	Hamdane, M. et al., "A Therapeutic Target in Alzheimer Neurodegeneration," <i>J. Mol. Neurosci.</i> , 19(3): 275-87 (2002).	<input type="checkbox"/>
21	Hardt, S.E. et al., "Glycogen Synthase Kinase-3β - A Novel Regulator of Cardiac Hypertrophy and Development," <i>Circulation Research</i> , 90: 1055-1063 (2002).	<input type="checkbox"/>
22	Parnell, E.W., "2-Cyano-4-nitrophenylhydrazine and 3-Amino-5-nitroindazole", <i>J. Chem. Soc.</i> , 2363-2365 (1959).	<input type="checkbox"/>
23	Heaney, F. et al., "Pyrimidine annelated heterocycles—synthesis and cycloaddition of the first pyrimido[1,4]diazepine N-oxides," <i>J. Chem. Soc., Perkin Trans. 1</i> , 622-632 (2001).	<input type="checkbox"/>
24	Hendriksen, E.J. et al., "Modulation of muscle insulin resistance by selective inhibition of GSK-3 in Zucker diabetic fatty rats," <i>Am. J. Physiol. Endocrinol. Metab.</i> , 284: E892-E900 (2003).	<input type="checkbox"/>
25	Okafor, C.O., "Studies in the Heterocyclic Series. X. 1,3,9-Triazaphenothiazine Ring System, a New Phenothiazine Ring," <i>J. Org. Chem.</i> , 40(19): 2753-2755 (1975).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775699
Filing Date	2004-02-10
First Named Inventor	David Bebbington
Art Unit	1624
Examiner Name	Tamthom Ngo Truong
Attorney Docket Number	VP1/00-130-07 DIV US

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

26	Jambhekar, S.S., "Biopharmaceutical Properties of Drug Substances" in Principles of Medicinal Chemistry, 4th ed., 12-24, (1995). <input type="checkbox"/>
27	Layzer, R.B., "Section Five - Degenerative Diseases of the Nervous System" in Cecil Textbook of Medicine, 20th ed., 2: 2050-2057 (1996). <input type="checkbox"/>
28	Lee, S.J. et. al., "Discovery of Potent Cyclic GMP Phosphodiesterase Inhibitors. 2-Pyridyl- and 2-Imidazolylquinazolines Possessing Cyclic GMP Phosphodiesterase and Thromboxane Synthesis Inhibitory Activities," J. Med. Chem., 38 (18): 3547-3557 (1995). <input type="checkbox"/>
29	Medwid, J.B. et al., "Preparation of Triazolo[1,5-c]pyrimidines as Potential Antiasthma Agents," J. Med. Chem. 33, 1230-1241 (1990). <input type="checkbox"/>
30	Nezu, Y. et al., "Dimethoxypyrimidines as Novel Herbicides. Part 1. Synthesis and Herbicidal Activity of Dimethoxyphenoxyphenoxypyrimidines and Analogues," Pestic. Sci., 47: 103-113 (1996). <input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Tamthom Truong/	Date Considered	02/08/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.